Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Its Implications for Prophylactic and Therapeutic Pharmaceuticals

Abstract

Respiratory syncytial virus (RSV) is a notorious pathogen that serves as the leading cause of lower respiratory tract infections (LRTI) among infants, the elderly, and immunocompromised individuals. Its widespread prevalence exerts a considerable burden on global healthcare systems and economies, owing to the high rates of hospitalization and the potential for long-term health complications. Significant progress has been achieved in RSV prevention strategies during recent years, with three vaccines currently approved worldwide for active immunization in adults aged 60 years and older, as well as pregnant women. Furthermore, the monoclonal antibody nirsevimab has been approved for the prevention of RSV infections in infants. However, effective antiviral treatments for postinfection cases remain an unmet clinical need. This review comprehensively elaborates the molecular and cellular mechanisms of RSV infection, including viral structure, replication cycle, and pathogenic mechanisms. Meanwhile, we systematically summarize the latest advances in preventive and therapeutic agents and analyze the practical applications and existing limitations of current immunization strategies. Furthermore, we discuss and propose the challenges and future directions in drug development. The review provide insights for developing novel and effective prevention and treatment strategies against RSV infection.

Keywords

pathogenic mechanisms / prophylactic strategies / respiratory syncytial virus / therapeutic strategies

References

[1] R. E. Blount, J. A. Morris, and R. E. Savage, “Recovery of Cytopathogenic Agent from Chimpanzees with coryza,” Proceedings of the Society for Experimental Biology and Medicine 92, no. 3 (1956): 544-549.

[2] R. Chanock, B. Roizman, and R. Myers, “Recovery from Infants with respiratory Illness of a Virus Related to Chimpanzee coryza Agent (CCA). I. Isolation, Properties and Characterization,” American Journal of Tropical Medicine and Hygiene 66, no. 3 (1957): 281-290.

[3] Y. Li, X. Wang, D. M. Blau, et al., “Global, Regional, and National Disease Burden Estimates of Acute Lower respiratory Infections due to respiratory Syncytial Virus in Children Younger than 5 Years in 2019: a Systematic Analysis,” Lancet 399, no. 10340 (2022): 2047-2064.

[4] T. Felicetti, C. Sarnari, R. Gaito, et al., “Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents,” Journal of Medicinal Chemistry 67, no. 14 (2024): 11543-11579.

[5] A. T. Borchers, C. Chang, M. E. Gershwin, et al., “Respiratory Syncytial Virus-a Comprehensive Review,” Clinical Reviews in Allergy & Immunology 45, no. 3 (2013): 331-379.

[6] C. Krempl, B. R. Murphy, and P. L. Collins, “Recombinant respiratory Syncytial Virus With the G and F Genes Shifted to the Promoter-proximal Positions,” Journal of Virology 76, no. 23 (2002): 11931-11942.

[7] M. Y. Jiang, Y. P. Duan, X. L. Tong, et al., “Clinical Manifestations of respiratory Syncytial Virus Infection and the Risk of Wheezing and Recurrent Wheezing Illness: a Systematic Review and Meta-analysis,” World Journal of Pediatrics 19, no. 11 (2023): 1030-1040.

[8] R. Ma, C. Zhang, Y. Zhang, et al., “The Impact of respiratory Syncytial Virus on Asthma Development and Exacerbation,” Annals of Allergy, Asthma & Immunology (2025).

[9] A. R. Branche, L. Saiman, E. E. Walsh, et al., “Incidence of Respiratory Syncytial Virus Infection among Hospitalized Adults, 2017-2020,” Clinical Infectious Diseases 74, no. 6 (2022): 1004-1011.

[10] N. Nziza, W. Jung, M. Mendu, et al., “Longitudinal Humoral Analysis in RSV-infected Infants Identifies Pre-existing RSV Strain-specific G and Evolving Cross-reactive F Antibodies,” Immunity 57, no. 7 (2024): 1681-1695. e1684.

[11] H. Guo-Parke, P. Canning, I. Douglas, et al., “Relative respiratory Syncytial Virus Cytopathogenesis in Upper and Lower respiratory Tract Epithelium,” American Journal of Respiratory and Critical Care Medicine 188, no. 7 (2013): 842-851.

[12] T. Tenenbaum, J. Liese, T. Welte, et al., “Respiratory Syncytial Virus-Associated Respiratory Diseases in Children and Adults,” Deutsches Ärzteblatt International 121, no. 9 (2024): 303-312.

[13] A. Britton, L. E. Roper, C. N. Kotton, et al., “Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2024,” Mmwr Morbidity and Mortality Weekly Report 73, no. 32 (2024): 696-702.

[14] Q. Li, H. Li, Z. Li, et al., “Vaccine and Therapeutic Agents against the respiratory Syncytial Virus: Resolved and Unresolved Issue,” MedComm 5, no. 12 (2024): e70016.

[15] I. Leroux-Roels, M. G. Davis, K. Steenackers, et al., “Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial,” Journal of Infectious Diseases 227, no. 6 (2023): 761-772.

[16] Y. K. Hong-Nguyen, J. Toerner, L. Lee, et al., “Regulatory Review of Benefits and Risks of Preventing Infant RSV Disease through Maternal Immunization,” NPJ Vaccines 9, no. 1 (2024): 210.

[17] C. C. Lai and P. R. Hsueh, “An Overview on Disease Burden and Management of Respiratory Syncytial Virus Infections in Older Adults in the Asia-Pacific Region,” Reviews in Medical Virology 34, no. 6 (2024): e70003.

[18] S. B. Drysdale, C. A. Green, and C. J. Sande, “Best Practice in the Prevention and Management of Paediatric respiratory Syncytial Virus Infection,” Therapeutic Advances in Infectious Disease 3, no. 2 (2016): 63-71.

[19] A. C. Langedijk, B. Vrancken, R. J. Lebbink, et al., “The Genomic Evolutionary Dynamics and Global Circulation Patterns of respiratory Syncytial Virus,” Nature Communications 15, no. 1 (2024): 3083.

[20] A. B. Yonts, C. Gaviria-Agudelo, A. J. Ratner, et al., “April 2025 ACIP Meeting Update: Influenza, COVID-19, HPV, RSV and Other Immunizations,” Pediatrics 156, no. 3 (2025): e2025072444.

[21] D. K. Shay, R. C. Holman, R. D. Newman, et al., “Bronchiolitis-associated Hospitalizations among US Children, 1980-1996,” Jama 282, no. 15 (1999): 1440-1446.

[22] S. Ostadabbas, C. Bulach, D. N. Ku, et al., “A Passive Quantitative Measurement of Airway Resistance Using Depth Data,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2014 (2014): 5743-5747.

[23] M. Hu, M. A. Bogoyevitch, and D. A. Jans, “Impact of Respiratory Syncytial Virus Infection on Host Functions: Implications for Antiviral Strategies,” Physiological Reviews 100, no. 4 (2020): 1527-1594.

[24] C. Griffiths, S. J. Drews, and D. J. Marchant, “Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment,” Clinical Microbiology Reviews 30, no. 1 (2017): 277-319.

[25] C. B. Hall, G. A. Weinberg, A. K. Blumkin, et al., “Respiratory Syncytial Virus-associated Hospitalizations among Children Less than 24 Months of Age,” Pediatrics 132, no. 2 (2013): e341-348.

[26] A. C. Langedijk and L. J. Bont, “Respiratory Syncytial Virus Infection and Novel Interventions,” Nature Reviews Microbiology 21, no. 11 (2023): 734-749.

[27] N. Haber, “Respiratory Syncytial Virus Infection in Elderly Adults,” Medecine Et Maladies Infectieuses 48, no. 6 (2018): 377-382.

[28] A. Chatterjee, K. Mavunda, and L. R. Krilov, “Current State of Respiratory Syncytial Virus Disease and Management,” Infectious Diseases and Therapy 10, no. Suppl 1 (2021): 5-16.

[29] M. Savic, Y. Penders, T. Shi, et al., “Respiratory Syncytial Virus Disease Burden in Adults Aged 60 Years and Older in High-income Countries: a Systematic Literature Review and Meta-analysis,” Influenza Other Respir Viruses 17, no. 1 (2023): e13031.

[30] A. Häder, N. Köse-Vogel, L. Schulz, et al., “Respiratory Infections in the Aging Lung: Implications for Diagnosis, Therapy, and Prevention,” Aging and Disease 14, no. 4 (2023): 1091-1104.

[31] A. Puggina, M. Dovizio, A. Domnich, et al., “Demographics and Clinical Burden of Disease among RSV-hospitalized Older Adults in Italy: a Retrospective Cohort Study,” Human Vaccines & Immunotherapeutics 21, no. 1 (2025): 2479334.

[32] A. R. Falsey, P. A. Hennessey, M. A. Formica, et al., “Respiratory Syncytial Virus Infection in Elderly and High-risk Adults,” New England Journal of Medicine 352, no. 17 (2005): 1749-1759.

[33] A. Mejias, R. Rodríguez-Fernández, S. Oliva, et al., “The Journey to a respiratory Syncytial Virus Vaccine,” Annals of Allergy, Asthma & Immunology 125, no. 1 (2020): 36-46.

[34] D. H. Villanueva, V. Arcega, and M. Rao, “Review of respiratory Syncytial Virus Infection among Older Adults and Transplant Recipients,” Therapeutic Advances in Infectious Disease 9 (2022): 20499361221091413.

[35] O. Chatzis, S. Darbre, J. Pasquier, et al., “Burden of Severe RSV Disease among Immunocompromised Children and Adults: a 10 Year Retrospective Study,” BMC Infectious Diseases [Electronic Resource] 18, no. 1 (2018): 111.

[36] S. Shan, W. Zhang, H. Gao, et al., “Global Seasonal Activities of Respiratory Syncytial Virus before the Coronavirus Disease 2019 Pandemic: a Systematic Review,” Open Forum Infectious Diseases 11, no. 5 (2024): ofae238.

[37] C. Azzari, E. Baraldi, P. Bonanni, et al., “Epidemiology and Prevention of respiratory Syncytial Virus Infections in Children in Italy,” Italian journal of pediatrics 47, no. 1 (2021): 198.

[38] Y. Li, R. M. Reeves, X. Wang, et al., “Global Patterns in Monthly Activity of Influenza Virus, respiratory Syncytial Virus, Parainfluenza Virus, and Metapneumovirus: a Systematic Analysis,” The Lancet Global Health 7, no. 8 (2019): e1031-e1045.

[39] K. Bloom-Feshbach, W. J. Alonso, V. Charu, et al., “Latitudinal Variations in Seasonal Activity of Influenza and respiratory Syncytial Virus (RSV): a Global Comparative Review,” PLoS ONE 8, no. 2 (2013): e54445.

[40] S. Janet, J. Broad, and M. D. Snape, “Respiratory Syncytial Virus Seasonality and Its Implications on Prevention Strategies,” Human vaccines & immunotherapeutics 14, no. 1 (2018): 234-244.

[41] M. F. Parry, A. K. Shah, M. Sestovic, et al., “Precipitous Fall in Common Respiratory Viral Infections during COVID-19,” Open Forum Infectious Diseases 7, no. 11 (2020): ofaa511.

[42] D. K. Yeoh, D. A. Foley, C. A. Minney-Smith, et al., “Impact of Coronavirus Disease 2019 Public Health Measures on Detections of Influenza and Respiratory Syncytial Virus in Children during the 2020 Australian Winter,” Clinical Infectious Diseases 72, no. 12 (2021): 2199-2202.

[43] L. Rodgers, M. Sheppard, A. Smith, et al., “Changes in Seasonal Respiratory Illnesses in the United States during the Coronavirus Disease 2019 (COVID-19) Pandemic,” Clinical Infectious Diseases 73, no. Suppl 1 (2021): S110-S117.

[44] C. Zhao, T. Zhang, L. Guo, et al., “Characterising the Asynchronous Resurgence of Common respiratory Viruses Following the COVID-19 Pandemic,” Nature Communications 16, no. 1 (2025): 1610.

[45] X. Xu, Y. Zhang, L. Xu, et al., “Analysis of respiratory Pathogen Detection in Hospitalized Children with Acute respiratory Tract Infections after Ending the Zero COVID Policy,” Scientific Reports 14, no. 1 (2024): 31784.

[46] C. M. Chan, A. A. Wahab, and A. Ali, “Assessing the Impact of COVID-19 on Epidemiological Changes of Severe Pediatric respiratory Syncytial Virus Infections in Malaysia,” Front Public Health 12 (2024): 1246921.

[47] E. Rios-Guzman, L. M. Simons, T. J. Dean, et al., “Deviations in RSV Epidemiological Patterns and Population Structures in the United States Following the COVID-19 Pandemic,” Nature Communications 15, no. 1 (2024): 3374.

[48] D. Thindwa, K. Li, D. Cooper-Wootton, et al., “Global Patterns of Rebound to Normal RSV Dynamics Following COVID-19 Suppression,” BMC Infectious Diseases [Electronic Resource] 24, no. 1 (2024): 635.

[49] L. Liljeroos, M. A. Krzyzaniak, A. Helenius, et al., “Architecture of respiratory Syncytial Virus Revealed by Electron Cryotomography,” PNAS 110, no. 27 (2013): 11133-11138.

[50] G. Kiss, J. M. Holl, G. M. Williams, et al., “Structural Analysis of respiratory Syncytial Virus Reveals the Position of M2-1 between the Matrix Protein and the ribonucleoprotein Complex,” Journal of Virology 88, no. 13 (2014): 7602-7617.

[51] Z. Ke, R. S. Dillard, T. Chirkova, et al., “The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography,” Viruses 10, no. 8 (2018): 446.

[52] E. De Clercq and G. Li, “Approved Antiviral Drugs over the Past 50 Years,” Clinical Microbiology Reviews 29, no. 3 (2016): 695-747.

[53] L. J. White, M. Waris, P. A. Cane, et al., “The Transmission Dynamics of Groups A and B human respiratory Syncytial Virus (hRSV) in England & Wales and Finland: Seasonality and Cross-protection,” Epidemiology and Infection 133, no. 2 (2005): 279-289.

[54] S. Esposito, A. Piralla, A. Zampiero, et al., “Characteristics and Their Clinical Relevance of Respiratory Syncytial Virus Types and Genotypes Circulating in Northern Italy in Five Consecutive Winter Seasons,” PLoS ONE 10, no. 6 (2015): e0129369.

[55] V. Bitko, O. Shulyayeva, B. Mazumder, et al., “Nonstructural Proteins of respiratory Syncytial Virus Suppress Premature Apoptosis by an NF-kappaB-dependent, Interferon-independent Mechanism and Facilitate Virus Growth,” Journal of Virology 81, no. 4 (2007): 1786-1795.

[56] T. N. Merritt, J. Pei, and D. W. Leung, “Pathogenicity and Virulence of human respiratory Syncytial Virus: Multifunctional Nonstructural Proteins NS1 and NS2,” Virulence (2023): 2283897.

[57] J. O. Ngwuta, M. Chen, K. Modjarrad, et al., “Prefusion F-specific Antibodies Determine the Magnitude of RSV Neutralizing Activity in human Sera,” Science Translational Medicine 7, no. 309 (2015): 309ra162.

[58] J. J. Mousa, N. Kose, P. Matta, et al., “A Novel Pre-fusion Conformation-specific Neutralizing Epitope on the respiratory Syncytial Virus Fusion Protein,” Nature microbiology 2 (2017): 16271.

[59] J. M. Langley, L. D. MacDonald, G. M. Weir, et al., “A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented with a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study,” Journal of Infectious Diseases 218, no. 3 (2018): 378-387.

[60] Y. Wang, C. Zhang, Y. Luo, et al., “Cryo-EM Structure of the Nucleocapsid-Like Assembly of respiratory Syncytial Virus,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 323.

[61] D. Cao, Y. Gao, and B. Liang, “Structural Insights into the Respiratory Syncytial Virus RNA Synthesis Complexes,” Viruses 13, no. 5 (2021): 834.

[62] J. Y. Lee and J. Chang, “Recombinant Baculovirus-based Vaccine Expressing M2 Protein Induces Protective CD8(+) T-cell Immunity against respiratory Syncytial Virus Infection,” Journal of Microbiology (Seoul, Korea) 55, no. 11 (2017): 900-908.

[63] R. Mitra, P. Baviskar, R. R. Duncan-Decocq, et al., “The human respiratory Syncytial Virus Matrix Protein Is Required for Maturation of Viral filaments,” Journal of Virology 86, no. 8 (2012): 4432-4443.

[64] B. Tian, J. Yang, Y. Zhao, et al., “Central Role of the NF-κB Pathway in the Scgb1a1-Expressing Epithelium in Mediating Respiratory Syncytial Virus-Induced Airway Inflammation,” Journal of Virology 92, no. 11 (2018): e00441-e00518.

[65] M. K. Lay, S. M. Bueno, N. Gálvez, et al., “New Insights on the Viral and Host Factors Contributing to the Airway Pathogenesis Caused by the respiratory Syncytial Virus,” Critical Reviews in Microbiology 42, no. 5 (2016): 800-812.

[66] J. Holguera, E. Villar, and I. Muñoz-Barroso, “Identification of Cellular Proteins That Interact with Newcastle Disease Virus and human Respiratory Syncytial Virus by a Two-dimensional Virus Overlay Protein Binding Assay (VOPBA),” Virus Research 191 (2014): 138-142.

[67] R. A. Tripp, L. P. Jones, L. M. Haynes, et al., “CX3C chemokine Mimicry by respiratory Syncytial Virus G Glycoprotein,” Nature Immunology 2, no. 8 (2001): 732-738.

[68] M. Donalisio, M. Rusnati, V. Cagno, et al., “Inhibition of human respiratory Syncytial Virus Infectivity by a Dendrimeric Heparan Sulfate-binding Peptide,” Antimicrobial Agents and Chemotherapy 56, no. 10 (2012): 5278-5288.

[69] Z. Shang, S. Tan, and D. Ma, “Respiratory Syncytial Virus: from Pathogenesis to Potential Therapeutic Strategies,” International Journal of Biological Sciences 17, no. 14 (2021): 4073-4091.

[70] S. Techaarpornkul, N. Barretto, and M. E. Peeples, “Functional Analysis of Recombinant respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene,” Journal of Virology 75, no. 15 (2001): 6825-6834.

[71] S. A. Feldman, S. Audet, and J. A. Beeler, “The Fusion Glycoprotein of human respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan Sulfate,” Journal of Virology 74, no. 14 (2000): 6442-6447.

[72] M. A. Krzyzaniak, M. T. Zumstein, J. A. Gerez, et al., “Host Cell Entry of respiratory Syncytial Virus Involves Macropinocytosis Followed by Proteolytic Activation of the F Protein,” Plos Pathogens 9, no. 4 (2013): e1003309.

[73] Q. J. Kieser, M. J. Granoski, R. D. McClelland, et al., “Actin Cytoskeleton Remodeling Disrupts Physical Barriers to Infection and Presents Entry Receptors to respiratory Syncytial Virus,” Journal of General Virology 104, no. 11 (2023): 001923.

[74] H. San-Juan-Vergara, V. Sampayo-Escobar, N. Reyes, et al., “Cholesterol-rich Microdomains as Docking Platforms for respiratory Syncytial Virus in Normal human Bronchial Epithelial Cells,” Journal of Virology 86, no. 3 (2012): 1832-1843.

[75] J. Risso-Ballester and M. A. Rameix-Welti, “Spatial Resolution of Virus Replication: RSV and Cytoplasmic Inclusion Bodies,” Advances in Virus Research 116 (2023): 1-43.

[76] M. B. Battles and J. S. McLellan, “Respiratory Syncytial Virus Entry and How to Block It,” Nature Reviews Microbiology 17, no. 4 (2019): 233-245.

[77] L. Kuo, H. Grosfeld, J. Cristina, et al., “Effects of Mutations in the Gene-start and Gene-end Sequence Motifs on Transcription of Monocistronic and Dicistronic Minigenomes of respiratory Syncytial Virus,” Journal of Virology 70, no. 10 (1996): 6892-6901.

[78] C. Z. Tremaglio, S. L. Noton, L. R. Deflubé, et al., “Respiratory Syncytial Virus Polymerase Can Initiate Transcription from Position 3 of the Leader Promoter,” Journal of Virology 87, no. 6 (2013): 3196-3207.

[79] Y. Gao, A. Raghavan, and S. A. Espinosa Garcia, “In Vitro Higher-order Oligomeric Assembly of the respiratory Syncytial Virus M2-1 Protein with Longer RNAs,” Journal of Virology 98, no. 8 (2024): e0104624.

[80] P. Sutto-Ortiz, S. Tcherniuk, N. Ysebaert, et al., “The Methyltransferase Domain of the Respiratory Syncytial Virus L Protein Catalyzes Cap N7 and 2'-O-methylation,” Plos Pathogens 17, no. 5 (2021): e1009562.

[81] P. Sutto-Ortiz, J. F. Eléouët, F. Ferron, et al., “Biochemistry of the Respiratory Syncytial Virus L Protein Embedding RNA Polymerase and Capping Activities,” Viruses 15, no. 2 (2023): 341.

[82] A. Bermingham and P. L. Collins, “The M2-2 Protein of human respiratory Syncytial Virus Is a Regulatory Factor Involved in the Balance between RNA Replication and Transcription,” PNAS 96, no. 20 (1999): 11259-11264.

[83] R. Fearns, P. L. Collins, and M. E. Peeples, “Functional Analysis of the Genomic and Antigenomic Promoters of human respiratory Syncytial Virus,” Journal of Virology 74, no. 13 (2000): 6006-6014.

[84] S. E. Bakker, S. Duquerroy, M. Galloux, et al., “The respiratory Syncytial Virus Nucleoprotein-RNA Complex Forms a Left-handed Helical Nucleocapsid,” Journal of General Virology 94, no. Pt 8 (2013): 1734-1738.

[85] R. Ghildyal, J. Mills, M. Murray, et al., “Respiratory Syncytial Virus Matrix Protein Associates with Nucleocapsids in Infected Cells,” Journal of General Virology 83, no. Pt 4 (2002): 753-757.

[86] F. Y. Shaikh and J. E. Crowe, “Molecular Mechanisms Driving respiratory Syncytial Virus Assembly,” Future Microbiol 8, no. 1 (2013): 123-131.

[87] G. Henderson, J. Murray, and R. P. Yeo, “Sorting of the respiratory Syncytial Virus Matrix Protein into Detergent-resistant Structures Is Dependent on Cell-surface Expression of the Glycoproteins,” Virology 300, no. 2 (2002): 244-254.

[88] R. Ghildyal, D. Li, I. Peroulis, et al., “Interaction between the respiratory Syncytial Virus G Glycoprotein Cytoplasmic Domain and the Matrix Protein,” Journal of General Virology 86, no. Pt 7 (2005): 1879-1884.

[89] J. Tian, K. Huang, S. Krishnan, et al., “RAGE Inhibits human respiratory Syncytial Virus Syncytium Formation by Interfering with F-protein Function,” Journal of General Virology 94, no. Pt 8 (2013): 1691-1700.

[90] K. A. Neilson and E. J. Yunis, “Demonstration of respiratory Syncytial Virus in an Autopsy Series,” Pediatric Pathology 10, no. 4 (1990): 491-502.

[91] P. Liu, M. Jamaluddin, K. Li, et al., “Retinoic Acid-inducible Gene I Mediates Early Antiviral Response and Toll-Like Receptor 3 Expression in respiratory Syncytial Virus-infected Airway Epithelial Cells,” Journal of Virology 81, no. 3 (2007): 1401-1411.

[92] Y. H. Wu, A. C. Lai, P. Y. Chi, et al., “Pulmonary IL-33 Orchestrates Innate Immune Cells to Mediate respiratory Syncytial Virus-evoked Airway Hyperreactivity and Eosinophilia,” Allergy 75, no. 4 (2020): 818-830.

[93] J. F. Bermejo-Martin, D. Bernardo, M. Dominguez-Gil, et al., “Interleukin (IL)-1beta, IL-6 and IL-8 in Nasal Secretions: a Common Role for Innate Immunity in Viral Bronchial Infection in Infants?,” British Journal of Biomedical Science 63, no. 4 (2006): 173-175.

[94] S. Tanaka, Y. Motomura, Y. Suzuki, et al., “The Enhancer HS2 Critically Regulates GATA-3-mediated Il4 Transcription in T(H)2 Cells,” Nature Immunology 12, no. 1 (2011): 77-85.

[95] S. J. Wadsworth, R. Atsuta, J. O. McIntyre, et al., “IL-13 and TH2 Cytokine Exposure Triggers Matrix Metalloproteinase 7-mediated Fas Ligand Cleavage from Bronchial Epithelial Cells,” Journal of Allergy and Clinical Immunology 126, no. 2 (2010): 366-374. e361-e368.

[96] J. Xu, G. K. Singhera, and D. R. Dorscheid, “Expression of Surfactant Protein D in Airways of Asthmatics and Interleukin-13 Modulation of Surfactant Protein D in human Models of Airway Epithelium,” Respiratory Research 16, no. 1 (2015): 26.

[97] N. C. M. Salfi, G. Vergine, M. Poloni, et al., “Fatal Deterioration of a Respiratory Syncytial Virus Infection in an Infant with Abnormal Muscularization of Intra-Acinar Pulmonary Arteries: Autopsy and Histological Findings,” Diagnostics (Basel) 14, no. 6 (2024): 601.

[98] B. Cortjens, O. J. de Boer, and R. de Jong, “Neutrophil Extracellular Traps Cause Airway Obstruction during respiratory Syncytial Virus Disease,” Journal of Pathology 238, no. 3 (2016): 401-411.

[99] G. A. Funchal, N. Jaeger, R. S. Czepielewski, et al., “Respiratory Syncytial Virus Fusion Protein Promotes TLR-4-dependent Neutrophil Extracellular Trap Formation by human Neutrophils,” PLoS ONE 10, no. 4 (2015): e0124082.

[100] R. M. Liesman, U. J. Buchholz, C. L. Luongo, et al., “RSV-encoded NS2 Promotes Epithelial Cell Shedding and Distal Airway Obstruction,” Journal of Clinical Investigation 124, no. 5 (2014): 2219-2233.

[101] Y. Wang, J. Zheng, X. Wang, et al., “Alveolar Macrophages and Airway Hyperresponsiveness Associated with respiratory Syncytial Virus Infection,” Frontiers in Immunology 13 (2022): 1012048.

[102] C. Zhao, A. E. Taliento, E. M. Belkin, et al., “Infant RSV Infection Desensitizes β2-adrenergic Receptor via CXCL11-CXCR7 Signaling in Airway Smooth Muscle,” BioRxiv (2025).

[103] J. R. Panuska, N. M. Cirino, F. Midulla, et al., “Productive Infection of Isolated human Alveolar Macrophages by respiratory Syncytial Virus,” Journal of Clinical Investigation 86, no. 1 (1990): 113-119.

[104] N. M. Cirino, J. R. Panuska, A. Villani, et al., “Restricted Replication of respiratory Syncytial Virus in human Alveolar Macrophages,” Journal of General Virology 74, no. Pt 8 (1993): 1527-1537.

[105] W. Song, S. Wei, and S. Matalon, “Inhibition of Epithelial Sodium Channels by respiratory Syncytial Virus in Vitro and in Vivo,” Annals of the New York Academy of Sciences 1203 (2010): 79-84.

[106] W. Song, G. Liu, C. A. Bosworth, et al., “Respiratory Syncytial Virus Inhibits Lung Epithelial Na+ Channels by Up-regulating Inducible Nitric-oxide Synthase,” Journal of Biological Chemistry 284, no. 11 (2009): 7294-7306.

[107] A. K. Olivier, J. M. Gallup, A. van Geelen, et al., “Exogenous Administration of Vascular Endothelial Growth Factor Prior to human respiratory Syncytial Virus a2 Infection Reduces Pulmonary Pathology in Neonatal Lambs and Alters Epithelial Innate Immune Responses,” Experimental Lung Research 37, no. 3 (2011): 131-143.

[108] J. E. Johnson, R. A. Gonzales, S. J. Olson, et al., “The Histopathology of Fatal Untreated human respiratory Syncytial Virus Infection,” Modern Pathology 20, no. 1 (2007): 108-119.

[109] V. Avadhanula, C. A. Rodriguez, J. P. Devincenzo, et al., “Respiratory Viruses Augment the Adhesion of Bacterial Pathogens to respiratory Epithelium in a Viral Species- and Cell Type-dependent Manner,” Journal of Virology 80, no. 4 (2006): 1629-1636.

[110] J. M. Hament, P. C. Aerts, A. Fleer, et al., “Enhanced Adherence of Streptococcus pneumoniae to human Epithelial Cells Infected with respiratory Syncytial Virus,” Pediatric Research 55, no. 6 (2004): 972-978.

[111] Z. Jiang, N. Nagata, E. Molina, et al., “Fimbria-mediated Enhanced Attachment of Nontypeable Haemophilus influenzae to respiratory Syncytial Virus-infected respiratory Epithelial Cells,” Infection and Immunity 67, no. 1 (1999): 187-192.

[112] W. Jiang, T. Wang, L. Li, et al., “Impact of Bacteria in Nasal Aspirates on Disease Severity of Bronchiolitis,” Infectious Diseases (London) 48, no. 1 (2016): 82-86.

[113] M. Jeannoël, G. Lina, J. P. Rasigade, et al., “Microorganisms Associated with respiratory Syncytial Virus Pneumonia in the Adult Population,” European Journal of Clinical Microbiology & Infectious Diseases 38, no. 1 (2019): 157-160.

[114] G. J. Escobar, A. Ragins, S. X. Li, et al., “Recurrent Wheezing in the Third Year of Life among Children Born at 32 Weeks' gestation or Later: Relationship to Laboratory-confirmed, Medically Attended Infection with respiratory Syncytial Virus during the First Year of Life,” Archives of Pediatrics & Adolescent Medicine 164, no. 10 (2010): 915-922.

[115] H. J. Zar, F. Cacho, T. Kootbodien, et al., “Early-life respiratory Syncytial Virus Disease and Long-term respiratory Health,” Lancet Respiratory Medicine 12, no. 10 (2024): 810-821.

[116] G. A. Prince, V. G. Hemming, R. L. Horswood, et al., “Intravenous Immune Serum Globulin (IVIG) for Prophylaxis and Treatment of respiratory Syncytial Virus (RSV) Infectione in the Cotton Rat,” Pediatric Research 18, no. 4 (1984): 284-284.

[117] V. G. Hemming, G. A. Prince, W. T. London, et al., “Intravenous Immune Globulin (IVIG) for the Treatment of respiratory Syncytial Virus (RSV) Infections: Studies in the Owl Monkey,” Pediatric Research 18, no. 4 (1984): 277-277.

[118] “Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.” Pediatrics 99, no. 4 (1997): 645-650.

[119] J. R. Groothuis, E. A. Simoes, M. J. Levin, et al., “Prophylactic Administration of respiratory Syncytial Virus Immune Globulin to High-risk Infants and Young Children. The Respiratory Syncytial Virus Immune Globulin Study Group,” New England Journal of Medicine 329, no. 21 (1993): 1524-1530.

[120] “Reduction of respiratory Syncytial Virus Hospitalization among Premature Infants and Infants with Bronchopulmonary Dysplasia Using respiratory Syncytial Virus Immune Globulin Prophylaxis. The PREVENT Study Group.” Pediatrics 99, no. 1 (1997): 93-99.

[121] E. A. Simoes, H. M. Sondheimer, and F. H. Top, “Respiratory Syncytial Virus Immune Globulin for Prophylaxis against respiratory Syncytial Virus Disease in Infants and Children with Congenital Heart Disease. The Cardiac Study Group,” Journal of Pediatrics 133, no. 4 (1998): 492-499.

[122] H. C. Bergeron and R. A. Tripp, “Emerging Small and Large Molecule Therapeutics for respiratory Syncytial Virus,” Expert Opinion on Investigational Drugs 29, no. 3 (2020): 285-294.

[123] M. Fadeyi and T. Tran, “Calculating the Dose of Subcutaneous Immunoglobulin for Primary Immunodeficiency Disease in Patients Switched from Intravenous to Subcutaneous Immunoglobulin without the Use of a Dose-adjustment Coefficient,” P I 38, no. 12 (2013): 768-770.

[124] M. L. Boyle and C. Scalchunes, “Impact of Intervenous Immunoglobulin (IVIG) Treatment among Patients with Primary Immunodeficiency Diseases,” Pharmaceuticals, Policy and Law 10 (2008): 133-146.

[125] M. Lucas, M. Lee, J. Lortan, et al., “Infection Outcomes in Patients with Common Variable Immunodeficiency Disorders: Relationship to Immunoglobulin Therapy over 22 Years,” Journal of Allergy and Clinical Immunology 125, no. 6 (2010): 1354-1360. e1354.

[126] R. L. Wasserman, B. N. Greener, and J. Mond, “RI-002, an Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other respiratory Viruses for Use in Primary Immunodeficiency Disease and Other Immune Compromised Populations,” Expert Review of Clinical Immunology 13, no. 12 (2017): 1107-1119.

[127] A. R. Falsey, C. Koval, J. P. DeVincenzo, et al., “Compassionate Use Experience with High-titer respiratory Syncytical Virus (RSV) Immunoglobulin in RSV-infected Immunocompromised Persons,” Transplant Infectious Disease: An Official Journal of the Transplantation Society 19, no. 2 (2017).

[128] R. L. Wasserman, W. Lumry, J. Harris, et al., “Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease,” Journal of Clinical Immunology 36, no. 6 (2016): 590-599.

[129] N. Lehners, P. Schnitzler, S. Geis, et al., “Risk Factors and Containment of respiratory Syncytial Virus Outbreak in a Hematology and Transplant Unit,” Bone Marrow Transplantation 48, no. 12 (2013): 1548-1553.

[130] J. J. Mond, “A High Titer Anti RSV Polyclonal Antibody (RI-002) Prevents Infection with Palivizumab Resistant (PR) RSV in Cotton Rats and Achieves Greater Neutralizing RSV Activity As Compared to Palivizumab,” Journal of Allergy and Clinical Immunology 137, no. 2 (2016): AB165.

[131] M. Boukhvalova, J. C. Blanco, A. R. Falsey, et al., “Treatment with Novel RSV Ig RI-002 Controls Viral Replication and Reduces Pulmonary Damage in Immunocompromised Sigmodon hispidus,” Bone Marrow Transplantation 51, no. 1 (2016): 119-126.

[132] J. S. Orange, W. Du, and A. R. Falsey, “Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV Also Contains High Antibody Titers to Other Respiratory Viruses,” Frontiers in immunology 6 (2015): 431.

[133] M. A. Ruffner, K. E. Sullivan, and S. E. Henrickson, “Recurrent and Sustained Viral Infections in Primary Immunodeficiencies,” Frontiers in immunology 8 (2017): 665.

[134] B. Diethelm-Varela, J. A. Soto, C. A. Riedel, et al., “New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus,” Infection and Drug Resistance 16 (2023): 2061-2074.

[135] J. S. McLellan, “Neutralizing Epitopes on the respiratory Syncytial Virus Fusion Glycoprotein,” Current opinion in virology 11 (2015): 70-75.

[136] T. J. Ruckwardt, K. M. Morabito, and B. S. Graham, “Immunological Lessons from Respiratory Syncytial Virus Vaccine Development,” Immunity 51, no. 3 (2019): 429-442.

[137] J. S. McLellan, W. C. Ray, and M. E. Peeples, “Structure and Function of respiratory Syncytial Virus Surface Glycoproteins,” Current Topics in Microbiology and Immunology 372 (2013): 83-104.

[138] J. S. McLellan, M. Chen, S. Leung, et al., “Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-specific Neutralizing Antibody,” Science 340, no. 6136 (2013): 1113-1117.

[139] J. S. McLellan, M. Chen, M. G. Joyce, et al., “Structure-based Design of a Fusion Glycoprotein Vaccine for respiratory Syncytial Virus,” Science 342, no. 6158 (2013): 592-598.

[140] C. Verwey, Z. Dangor, and S. A. Madhi, “Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date,” Paediatric Drugs 26, no. 2 (2024): 101-112.

[141] “Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-risk Infants.” Pediatrics 102, no. 3 (1998): 531-537.

[142] “Updated Guidance for Palivizumab Prophylaxis among Infants and Young Children at Increased Risk of Hospitalization for respiratory Syncytial Virus Infection.” Pediatrics 134, no. 2 (2014): 415-420.

[143] C. J. Grindeland, C. T. Mauriello, D. D. Leedahl, et al., “Association between Updated Guideline-Based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections,” Pediatric Infectious Disease Journal 35, no. 7 (2016): 728-732.

[144] H. Wu, D. S. Pfarr, S. Johnson, et al., “Development of motavizumab, an Ultra-potent Antibody for the Prevention of respiratory Syncytial Virus Infection in the Upper and Lower respiratory Tract,” Journal of Molecular Biology 368, no. 3 (2007): 652-665.

[145] A. Mejías, S. Chávez-Bueno, M. B. Raynor, et al., “Motavizumab, a Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies the Local and Systemic Cytokine Responses Induced by Rsv in the Mouse Model,” Virology journal 4 (2007): 109.

[146] A. Mejías, S. Chávez-Bueno, A. M. Ríos, et al., “Comparative Effects of Two Neutralizing Anti-respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus Potency,” Antimicrobial Agents and Chemotherapy 49, no. 11 (2005): 4700-4707.

[147] K. Abarca, E. Jung, P. Fernández, et al., “Safety, Tolerability, Pharmacokinetics, and Immunogenicity of motavizumab, a Humanized, Enhanced-potency Monoclonal Antibody for the Prevention of respiratory Syncytial Virus Infection in at-risk Children,” Pediatric Infectious Disease Journal 28, no. 4 (2009): 267-272.

[148] X. Carbonell-Estrany, E. A. Simões, R. Dagan, et al., “Motavizumab for Prophylaxis of respiratory Syncytial Virus in High-risk Children: a Noninferiority Trial,” Pediatrics 125, no. 1 (2010): e35-51.

[149] T. F. Feltes, H. M. Sondheimer, R. M. Tulloh, et al., “A Randomized Controlled Trial of motavizumab versus palivizumab for the Prophylaxis of Serious respiratory Syncytial Virus Disease in Children with Hemodynamically Significant Congenital Heart Disease,” Pediatric Research 70, no. 2 (2011): 186-191.

[150] J. M. Reichert, “Antibodies to Watch in 2017,” MAbs 9, no. 2 (2017): 167-181.

[151] E. A. F. Simões, E. Forleo-Neto, G. P. Geba, et al., “Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants,” Clinical Infectious Diseases 73, no. 11 (2021): e4400-e4408.

[152] S. J. Keam, “Nirsevimab: First Approval,” Drugs 83, no. 2 (2023): 181-187.

[153] S. C. J. Jorgensen, “Nirsevimab: Review of Pharmacology, Antiviral Activity and Emerging Clinical Experience for respiratory Syncytial Virus Infection in Infants,” Journal of Antimicrobial Chemotherapy 78, no. 5 (2023): 1143-1149.

[154] M. P. Griffin, A. A. Khan, M. T. Esser, et al., “Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults,” Antimicrobial Agents and Chemotherapy 61, no. 3 (2017): e01714-e01716.

[155] M. P. Griffin, Y. Yuan, T. Takas, et al., “Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants,” New England Journal of Medicine 383, no. 5 (2020): 415-425.

[156] L. L. Hammitt, R. Dagan, Y. Yuan, et al., “Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants,” New England Journal of Medicine 386, no. 9 (2022): 837-846.

[157] R. Dagan, L. L. Hammitt, B. S. Nuñez, et al., “Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season,” Journal of the Pediatric Infectious Diseases Society 13, no. 2 (2024): 144-147.

[158] J. Domachowske, S. A. Madhi, E. A. F. Simões, et al., “Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity,” New England Journal of Medicine 386, no. 9 (2022): 892-894.

[159] A. Nazir, R. Fatima, and A. Nazir, “FDA Grants Approval to the RSV Vaccine (nirsevimab-alip) for all Infants: a Leap Forward for Shielding the Smallest,” International Journal of Surgery 109, no. 12 (2023): 3745-3746.

[160] S. Ares-Gómez, N. Mallah, M. I. Santiago-Pérez, et al., “Effectiveness and Impact of Universal Prophylaxis with nirsevimab in Infants against Hospitalisation for respiratory Syncytial Virus in Galicia, Spain: Initial Results of a Population-based Longitudinal Study,” The Lancet Infectious Diseases 24, no. 8 (2024): 817-828.

[161] S. Anderer, “Nirsevimab Provides Real-World RSV Protection in Infants,” Jama 334, no. 2 (2025): 107.

[162] D. M. Sumsuzzman, Z. Wang, J. M. Langley, et al., “Real-world Effectiveness of nirsevimab against respiratory Syncytial Virus Disease in Infants: a Systematic Review and Meta-analysis,” The Lancet Child & Adolescent Health 9, no. 6 (2025): 393-403.

[163] A. Tang, Z. Chen, K. S. Cox, et al., “A Potent Broadly Neutralizing human RSV Antibody Targets Conserved Site IV of the Fusion Glycoprotein,” Nature Communications 10, no. 1 (2019): 4153.

[164] A. O. Aliprantis, D. Wolford, L. Caro, et al., “A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults,” Clinical Pharmacology in Drug Development 10, no. 5 (2021): 556-566.

[165] R. R. Brian Maas and X. Cao, Pharmacokinetics, serum-neutralizing activity, and efficacy From a phase 1b/2a infant study of clesrovimab (MK-1654), an RSV- neutralizing monoclonal antibody (European Society for Pediatric Infectious Diseases, 2023), https://cslide.ctimeetingtech.com/espid23/attendee/confcal/show/session/82.

[166] S. A. Madhi, E. A. F. Simões, A. Acevedo, et al., “A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants,” Journal of Infectious Diseases 231, no. 3 (2025): e478-e487.

[167] J. Terstappen, E. M. Delemarre, A. Versnel, et al., “RSV Neutralizing Antibodies in Dried Blood,” Journal of Infectious Diseases 230, no. 1 (2024): e93-e101.

[168] J. Ananworanich and P. M. Heaton, “Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities,” Vaccines (Basel) 9, no. 9 (2021): 961.

[169] M. Levi, S. Watson, A. B. Anderson, et al., “383. Pharmacokinetics and Safety in Healthy Adults of RSM01, a Novel RSV Monoclonal Antibody, and Population PK Modeling to Support Pediatric Development,” Open Forum Infectious Diseases 10, no. Supplement_2 (2023): ofad500/453.

[170] G. W. Wertz, P. L. Collins, Y. Huang, et al., “Nucleotide Sequence of the G Protein Gene of human respiratory Syncytial Virus Reveals an Unusual Type of Viral Membrane Protein,” PNAS 82, no. 12 (1985): 4075-4079.

[171] P. L. Collins and G. Mottet, “Oligomerization and Post-translational Processing of Glycoprotein g of human respiratory Syncytial Virus: Altered O-glycosylation in the Presence of Brefeldin A,” Journal of General Virology 73, no. Pt 4 (1992): 849-863.

[172] H. G. Jones, T. Ritschel, G. Pascual, et al., “Structural Basis for Recognition of the central Conserved Region of RSV g by Neutralizing human Antibodies,” Plos Pathogens 14, no. 3 (2018): e1006935.

[173] J. P. Langedijk, W. M. Schaaper, R. H. Meloen, et al., “Proposed Three-dimensional Model for the Attachment Protein G of respiratory Syncytial Virus,” Journal of General Virology 77, no. Pt 6 (1996): 1249-1257.

[174] J. J. Gorman, B. L. Ferguson, D. Speelman, et al., “Determination of the Disulfide Bond Arrangement of human respiratory Syncytial Virus Attachment (G) Protein by Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry,” Protein Science 6, no. 6 (1997): 1308-1315.

[175] S. A. Feldman, R. M. Hendry, and J. A. Beeler, “Identification of a Linear Heparin Binding Domain for human respiratory Syncytial Virus Attachment Glycoprotein G,” Journal of Virology 73, no. 8 (1999): 6610-6617.

[176] B. Shields, J. Mills, R. Ghildyal, et al., “Multiple Heparin Binding Domains of respiratory Syncytial Virus G Mediate Binding to Mammalian Cells,” Archives of Virology 148, no. 10 (2003): 1987-2003.

[177] P. R. Johnson, M. K. Spriggs, R. A. Olmsted, et al., “The G Glycoprotein of human respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence between Antigenically Related Proteins,” PNAS 84, no. 16 (1987): 5625-5629.

[178] A. Bukreyev, L. Yang, J. Fricke, et al., “The Secreted Form of respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-bearing Leukocytes,” Journal of Virology 82, no. 24 (2008): 12191-12204.

[179] D. A. Hendricks, K. Baradaran, K. McIntosh, et al., “Appearance of a Soluble Form of the G Protein of respiratory Syncytial Virus in Fluids of Infected Cells,” Journal of General Virology 68, no. Pt 6 (1987): 1705-1714.

[180] O. García, M. Martín, J. Dopazo, et al., “Evolutionary Pattern of human respiratory Syncytial Virus (subgroup A): Cocirculating Lineages and Correlation of Genetic and Antigenic Changes in the G Glycoprotein,” Journal of Virology 68, no. 9 (1994): 5448-5459.

[181] J. A. Melero, B. García-Barreno, I. Martínez, et al., “Antigenic Structure, Evolution and Immunobiology of human respiratory Syncytial Virus Attachment (G) Protein,” Journal of General Virology 78, no. Pt 10 (1997): 2411-2418.

[182] I. Martínez, J. Dopazo, and J. A. Melero, “Antigenic Structure of the human respiratory Syncytial Virus G Glycoprotein and Relevance of Hypermutation Events for the Generation of Antigenic Variants,” Journal of General Virology 78, no. Pt 10 (1997): 2419-2429.

[183] J. Rawling and J. A. Melero, “The Use of Monoclonal Antibodies and Lectins to Identify Changes in Viral Glycoproteins That Are Influenced by Glycosylation: The Case of human respiratory Syncytial Virus Attachment (G) Glycoprotein,” Methods in Molecular Biology 379 (2007): 109-125.

[184] A. Eshaghi, V. R. Duvvuri, R. Lai, et al., “Genetic Variability of human respiratory Syncytial Virus A Strains Circulating in Ontario: a Novel Genotype with a 72 Nucleotide G Gene Duplication,” PLoS ONE 7, no. 3 (2012): e32807.

[185] K. Yoshihara, M. N. Le, M. Okamoto, et al., “Association of RSV-A ON1 Genotype with Increased Pediatric Acute Lower Respiratory Tract Infection in Vietnam,” Scientific Reports 6 (2016): 27856.

[186] H. J. Lee, J. Y. Lee, M. H. Park, et al., “Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance in Vivo and Prevents Vaccine-Enhanced Diseases,” PLoS ONE 12, no. 1 (2017): e0169139.

[187] J. Han, K. Takeda, M. Wang, et al., “Effects of Anti-g and Anti-f Antibodies on Airway Function after respiratory Syncytial Virus Infection,” American Journal of Respiratory Cell and Molecular Biology 51, no. 1 (2014): 143-154.

[188] J. Harcourt, R. Alvarez, L. P. Jones, et al., “Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses,” Journal of Immunology 176, no. 3 (2006): 1600-1608.

[189] L. M. Haynes, H. Caidi, G. U. Radu, et al., “Therapeutic Monoclonal Antibody Treatment Targeting respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice,” Journal of Infectious Diseases 200, no. 3 (2009): 439-447.

[190] C. Miao, G. U. Radu, H. Caidi, et al., “Treatment with respiratory Syncytial Virus G Glycoprotein Monoclonal Antibody or F(ab')2 Components Mediates Reduced Pulmonary Inflammation in Mice,” Journal of General Virology 90, no. Pt 5 (2009): 1119-1123.

[191] S. Boyoglu-Barnum, K. A. Gaston, S. O. Todd, et al., “A respiratory Syncytial Virus (RSV) Anti-G Protein F(ab')2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-infected BALB/c Mice,” Journal of Virology 87, no. 20 (2013): 10955-10967.

[192] G. U. Radu, H. Caidi, C. Miao, et al., “Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in respiratory Syncytial Virus (RSV)-challenged Naive and Formalin-inactivated RSV-immunized BALB/c Mice,” Journal of Virology 84, no. 18 (2010): 9632-9636.

[193] S. Boyoglu-Barnum, S. O. Todd, T. Chirkova, et al., “An Anti-G Protein Monoclonal Antibody Treats RSV Disease More Effectively than an Anti-F Monoclonal Antibody in BALB/c Mice,” Virology 483 (2015): 117-125.

[194] H. Caidi, C. Miao, N. J. Thornburg, et al., “Anti-respiratory Syncytial Virus (RSV) G Monoclonal Antibodies Reduce Lung Inflammation and Viral Lung Titers When Delivered Therapeutically in a BALB/c Mouse Model,” Antiviral Research 154 (2018): 149-157.

[195] E. J. Collarini, F. E. Lee, O. Foord, et al., “Potent High-affinity Antibodies for Treatment and Prophylaxis of respiratory Syncytial Virus Derived from B Cells of Infected Patients,” Journal of Immunology 183, no. 10 (2009): 6338-6345.

[196] M. Arbabi-Ghahroudi, “Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook,” Frontiers in immunology 8 (2017): 1589.

[197] L. Detalle, T. Stohr, C. Palomo, et al., “Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection,” Antimicrobial Agents and Chemotherapy 60, no. 1 (2016): 6-13.

[198] G. Van Heeke, K. Allosery, V. De Brabandere, et al., “Nanobodies as Inhaled Biotherapeutics for Lung Diseases,” Pharmacology & Therapeutics 169 (2017): 47-56.

[199] C. Palomo, V. Mas, L. Detalle, et al., “Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection,” Antimicrobial Agents and Chemotherapy 60, no. 11 (2016): 6498-6509.

[200] A. Larios Mora, L. Detalle, and J. M. Gallup, “Delivery of ALX-0171 by Inhalation Greatly Reduces respiratory Syncytial Virus Disease in Newborn Lambs,” MAbs 10, no. 5 (2018): 778-795.

[201] S. Cunningham, P. A. Piedra, F. Martinon-Torres, et al., “Nebulised ALX-0171 for respiratory Syncytial Virus Lower respiratory Tract Infection in Hospitalised Children: a Double-blind, Randomised, Placebo-controlled, Phase 2b Trial,” Lancet Respiratory Medicine 9, no. 1 (2021): 21-32.

[202] G. Zou, S. Cao, Z. Gao, et al., “Current state and Challenges in respiratory Syncytial Virus Drug Discovery and Development,” Antiviral Research 221 (2024): 105791.

[203] G. Bolt, L. O. Pedersen, and H. H. Birkeslund, “Cleavage of the respiratory Syncytial Virus Fusion Protein Is Required for Its Surface Expression: Role of Furin,” Virus Research 68, no. 1 (2000): 25-33.

[204] Z. Sun, Y. Pan, S. Jiang, et al., “Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein,” Viruses 5, no. 1 (2013): 211-225.

[205] A. Krarup, D. Truan, P. Furmanova-Hollenstein, et al., “A Highly Stable Prefusion RSV F Vaccine Derived from Structural Analysis of the Fusion Mechanism,” Nature Communications 6 (2015): 8143.

[206] G. Zimmer, L. Budz, and G. Herrler, “Proteolytic Activation of respiratory Syncytial Virus Fusion Protein. Cleavage at Two Furin Consensus Sequences,” Journal of Biological Chemistry 276, no. 34 (2001): 31642-31650.

[207] K. A. Swanson, E. C. Settembre, C. A. Shaw, et al., “Structural Basis for Immunization with Postfusion respiratory Syncytial Virus Fusion F Glycoprotein (RSV F) to Elicit High Neutralizing Antibody Titers,” PNAS 108, no. 23 (2011): 9619-9624.

[208] M. S. Gilman, S. M. Moin, V. Mas, et al., “Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein,” Plos Pathogens 11, no. 7 (2015): e1005035.

[209] N. Srinivasakumar, P. L. Ogra, and T. D. Flanagan, “Characteristics of Fusion of respiratory Syncytial Virus with HEp-2 Cells as Measured by R18 Fluorescence Dequenching Assay,” Journal of Virology 65, no. 8 (1991): 4063-4069.

[210] R. A. Karron, D. A. Buonagurio, A. F. Georgiu, et al., “Respiratory Syncytial Virus (RSV) SH and G Proteins Are Not Essential for Viral Replication in Vitro: Clinical Evaluation and Molecular Characterization of a Cold-passaged, Attenuated RSV Subgroup B Mutant,” PNAS 94, no. 25 (1997): 13961-13966.

[211] A. A. Kolokoltsov, D. Deniger, E. H. Fleming, et al., “Small Interfering RNA Profiling Reveals Key Role of Clathrin-mediated Endocytosis and Early Endosome Formation for Infection by respiratory Syncytial Virus,” Journal of Virology 81, no. 14 (2007): 7786-7800.

[212] J. S. McLellan, Y. Yang, B. S. Graham, et al., “Structure of respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes,” Journal of Virology 85, no. 15 (2011): 7788-7796.

[213] X. Zhao, M. Singh, V. N. Malashkevich, et al., “Structural Characterization of the human respiratory Syncytial Virus Fusion Protein Core,” PNAS 97, no. 26 (2000): 14172-14177.

[214] J. M. Matthews, T. F. Young, S. P. Tucker, et al., “The Core of the respiratory Syncytial Virus Fusion Protein Is a Trimeric Coiled Coil,” Journal of Virology 74, no. 13 (2000): 5911-5920.

[215] D. Samuel, W. Xing, A. Niedziela-Majka, et al., “GS-5806 Inhibits Pre- to Postfusion Conformational Changes of the respiratory Syncytial Virus Fusion Protein,” Antimicrobial Agents and Chemotherapy 59, no. 11 (2015): 7109-7112.

[216] D. Roymans, S. S. Alnajjar, M. B. Battles, et al., “Therapeutic Efficacy of a respiratory Syncytial Virus Fusion Inhibitor,” Nature Communications 8, no. 1 (2017): 167.

[217] J. L. Douglas, M. L. Panis, E. Ho, et al., “Small Molecules VP-14637 and JNJ-2408068 Inhibit respiratory Syncytial Virus Fusion by Similar Mechanisms,” Antimicrobial Agents and Chemotherapy 49, no. 6 (2005): 2460-2466.

[218] M. B. Battles, J. P. Langedijk, P. Furmanova-Hollenstein, et al., “Molecular Mechanism of respiratory Syncytial Virus Fusion Inhibitors,” Nature Chemical Biology 12, no. 2 (2016): 87-93.

[219] R. L. Mackman, M. Sangi, D. Sperandio, et al., “Discovery of an Oral respiratory Syncytial Virus (RSV) Fusion Inhibitor (GS-5806) and Clinical Proof of Concept in a human RSV Challenge Study,” Journal of Medicinal Chemistry 58, no. 4 (2015): 1630-1643.

[220] J. P. DeVincenzo, R. J. Whitley, R. L. Mackman, et al., “Oral GS-5806 Activity in a respiratory Syncytial Virus Challenge Study,” New England Journal of Medicine 371, no. 8 (2014): 711-722.

[221] R. F. Chemaly, S. S. Dadwal, A. Bergeron, et al., “A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients,” Clinical Infectious Diseases 71, no. 11 (2020): 2777-2786.

[222] F. M. Marty, R. F. Chemaly, K. M. Mullane, et al., “A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract,” Clinical Infectious Diseases 71, no. 11 (2020): 2787-2795.

[223] J. Gottlieb, F. Torres, T. Haddad, et al., “A Randomized Controlled Trial of presatovir for respiratory Syncytial Virus after Lung Transplant,” Journal of Heart and Lung Transplantation 42, no. 7 (2023): 908-916.

[224] M. Stevens, S. Rusch, J. DeVincenzo, et al., “Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged with Respiratory Syncytial Virus: a Placebo-Controlled Study,” Journal of Infectious Diseases 218, no. 5 (2018): 748-756.

[225] F. Martinón-Torres, S. Rusch, D. Huntjens, et al., “Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized with RSV Infection: a Randomized Phase 1b Study,” Clinical Infectious Diseases 71, no. 10 (2020): e594-e603.

[226] A. C. Nilsson, J. Pullman, P. Napora, et al., “A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, and Tolerability of rilematovir at Two Dose Levels in Non-hospitalized Adults with respiratory Syncytial Virus Infection,” Clinical Microbiology and Infection 29, no. 10 (2023): 1320-1327.

[227] F. Ferrero, C. Y. Lin, J. Liese, et al., “CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection due to Respiratory Syncytial Virus,” Paediatric Drugs 26, no. 4 (2024): 411-427.

[228] K. Andries, M. Moeremans, T. Gevers, et al., “Substituted Benzimidazoles with Nanomolar Activity against respiratory Syncytial Virus,” Antiviral Research 60, no. 3 (2003): 209-219.

[229] P. R. Wyde, S. N. Chetty, P. Timmerman, et al., “Short Duration Aerosols of JNJ 2408068 (R170591) Administered Prophylactically or Therapeutically Protect Cotton Rats from Experimental respiratory Syncytial Virus Infection,” Antiviral Research 60, no. 3 (2003): 221-231.

[230] J. F. Bonfanti, F. Doublet, J. Fortin, et al., “Selection of a respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate, Part 1: Improving the Pharmacokinetic Profile Using the Structure-property Relationship,” Journal of Medicinal Chemistry 50, no. 19 (2007): 4572-4584.

[231] D. Roymans, H. L. De Bondt, E. Arnoult, et al., “Binding of a Potent Small-molecule Inhibitor of Six-helix Bundle Formation Requires Interactions with both Heptad-repeats of the RSV Fusion Protein,” PNAS 107, no. 1 (2010): 308-313.

[232] W. Olszewska, G. Ispas, C. Schnoeller, et al., “Antiviral and Lung Protective Activity of a Novel respiratory Syncytial Virus Fusion Inhibitor in a Mouse Model,” European Respiratory Journal 38, no. 2 (2011): 401-408.

[233] G. Ispas, A. Koul, J. Verbeeck, et al., “Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model,” PLoS ONE 10, no. 5 (2015): e0126959.

[234] E. Heylen, J. Neyts, and D. Jochmans, “Drug Candidates and Model Systems in respiratory Syncytial Virus Antiviral Drug Discovery,” Biochemical Pharmacology 127 (2017): 1-12.

[235] A. T. K. Sevendal, S. Hurley, A. W. Bartlett, et al., “Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development,” Reviews in Medical Virology 34, no. 5 (2024): e2576.

[236] J. L. Douglas, M. L. Panis, E. Ho, et al., “Inhibition of respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein,” Journal of Virology 77, no. 9 (2003): 5054-5064.

[237] P. A. Jorquera and R. A. Tripp, “Respiratory Syncytial Virus: Prospects for New and Emerging Therapeutics,” Expert Review of Respiratory Medicine 11, no. 8 (2017): 609-615.

[238] Y. I. Kim, R. Pareek, R. Murphy, et al., “The Antiviral Effects of RSV Fusion Inhibitor, MDT-637, on Clinical Isolates, vs Its Achievable Concentrations in the human respiratory Tract and Comparison to Ribavirin,” Influenza Other Respir Viruses 11, no. 6 (2017): 525-530.

[239] X. Zheng, L. Gao, L. Wang, et al., “Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor,” Journal of Medicinal Chemistry 62, no. 13 (2019): 6003-6014.

[240] J. W. S. Toovey, V. Wang, P. Griffin, A. Lau, and S. Elliot, “Safety and Pharmacokinetics in Healthy Volunteers of the Anti-RSV Antiviral AK0529,” 1st International Meeting on Respiratory Pathogens; 2015; Singapore.

[241] L. M. Huang, A. Schibler, Y. C. Huang, et al., “Safety and Efficacy of AK0529 in respiratory Syncytial Virus-infected Infant Patients: a Phase 2 Proof-of-concept Trial,” Influenza Other Respir Viruses 17, no. 7 (2023): e13176.

[242] A. Biosciences. Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium. 2022, https://www.arkbiosciences.com/en_2022n/112.

[243] S. Zhao, Y. Shang, Y. Yin, et al., “Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection,” New England Journal of Medicine 391, no. 12 (2024): 1096-1107.

[244] E. E. Walsh, “Creeping toward Effective Antiviral Agents for RSV Infection,” New England Journal of Medicine 391, no. 12 (2024): 1155-1156.

[245] H. Zhang, W. Zhao, X. Zhang, et al., “Efficacy and Safety of ziresovir in Hospitalised Infants Aged 6 Months or Younger with respiratory Syncytial Virus Infection in China: Findings from a Phase 3 Randomised Trial with 24-month Follow-up,” Lancet Child Adolesc Health 9, no. 5 (2025): 325-336.

[246] G. S. Cockerill, R. M. Angell, A. Bedernjak, et al., “Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion,” Journal of Medicinal Chemistry 64, no. 7 (2021): 3658-3676.

[247] J. DeVincenzo, D. Tait, J. Efthimiou, et al., “A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein,” Antimicrobial Agents and Chemotherapy 64, no. 2 (2020).

[248] Y. Duan, Z. Liu, N. Zang, et al., “Landscape of respiratory Syncytial Virus,” Chinese Medical Journal 137, no. 24 (2024): 2953-2978.

[249] S. M. Sake, X. Zhang, M. K. Rajak, et al., “Drug Repurposing Screen Identifies lonafarnib as respiratory Syncytial Virus Fusion Protein Inhibitor,” Nature Communications 15, no. 1 (2024): 1173.

[250] Q. Yang, B. Xue, F. Liu, et al., “Farnesyltransferase Inhibitor Lonafarnib Suppresses respiratory Syncytial Virus Infection by Blocking Conformational Change of Fusion Glycoprotein,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 144.

[251] D. Cao, Y. Gao, Z. Chen, et al., “Structures of the Promoter-bound respiratory Syncytial Virus Polymerase,” Nature 625, no. 7995 (2024): 611-617.

[252] M. Wang, R. Li, B. Shu, et al., “Stringent Control of the RNA-dependent RNA Polymerase Translocation Revealed by Multiple Intermediate Structures,” Nature Communications 11, no. 1 (2020): 2605.

[253] S. Pathania, R. K. Rawal, and P. K. Singh, “RdRp (RNA-dependent RNA polymerase): a Key Target Providing Anti-virals for the Management of Various Viral Diseases,” Journal of Molecular Structure 1250 (2022): 131756.

[254] M. S. A. Gilman, C. Liu, A. Fung, et al., “Structure of the Respiratory Syncytial Virus Polymerase Complex,” Cell 179, no. 1 (2019): 193-204. e114.

[255] D. Garriga, C. Ferrer-Orta, J. Querol-Audí, et al., “Role of Motif B Loop in Allosteric Regulation of RNA-dependent RNA Polymerization Activity,” Journal of Molecular Biology 425, no. 13 (2013): 2279-2287.

[256] J. Deval, A. Fung, S. K. Stevens, et al., “Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase,” PLoS ONE 11, no. 5 (2016): e0154097.

[257] K. Patel, C. M. Kirkpatrick, K. A. Nieforth, et al., “Respiratory Syncytial Virus-A Dynamics and the Effects of Lumicitabine, a Nucleoside Viral Replication Inhibitor, in Experimentally Infected Humans,” Journal of Antimicrobial Chemotherapy 74, no. 2 (2019): 442-452.

[258] J. Deval, J. Hong, G. Wang, et al., “Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate,” Plos Pathogens 11, no. 6 (2015): e1004995.

[259] J. P. DeVincenzo, M. W. McClure, J. A. Symons, et al., “Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study,” New England Journal of Medicine 373, no. 21 (2015): 2048-2058.

[260] A. Oey, M. McClure, J. A. Symons, et al., “Lumicitabine, an Orally Administered Nucleoside Analog, in Infants Hospitalized with respiratory Syncytial Virus (RSV) Infection: Safety, Efficacy, and Pharmacokinetic Results,” PLoS ONE 18, no. 7 (2023): e0288271.

[261] E. P. Tchesnokov, J. Y. Feng, D. P. Porter, et al., “Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir,” Viruses 11, no. 4 (2019): 326.

[262] R. L. Mackman, H. C. Hui, M. Perron, et al., “Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV,” Journal of Medicinal Chemistry 64, no. 8 (2021): 5001-5017.

[263] R. L. Mackman, “Phosphoramidate Prodrugs Continue to Deliver, the Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2,” Acs Medicinal Chemistry Letters 13, no. 3 (2022): 338-347.

[264] M. Coates, D. Brookes, Y. I. Kim, et al., “Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor,” Antimicrobial Agents and Chemotherapy 61, no. 9 (2017): e00737-e00817.

[265] E. B. Atchison, S. N. Croft, C. Mathew, et al., “Interaction between the Matrix Protein and the Polymerase Complex of Respiratory Syncytial Virus,” Viruses 16, no. 12 (2024): 1881.

[266] D. W. Brookes, M. Coates, H. Allen, et al., “Late Therapeutic Intervention with a respiratory Syncytial Virus L-protein Polymerase Inhibitor, PC786, on respiratory Syncytial Virus Infection in human Airway Epithelium,” British Journal of Pharmacology 175, no. 12 (2018): 2520-2534.

[267] J. DeVincenzo, L. Cass, A. Murray, et al., “Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study,” Journal of Infectious Diseases 225, no. 12 (2022): 2087-2096.

[268] C. L. Tiong-Yip, L. Aschenbrenner, K. D. Johnson, et al., “Characterization of a respiratory Syncytial Virus L Protein Inhibitor,” Antimicrobial Agents and Chemotherapy 58, no. 7 (2014): 3867-3873.

[269] S. L. Noton, K. Nagendra, E. F. Dunn, et al., “Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter,” Journal of Virology 89, no. 15 (2015): 7786-7798.

[270] X. Yu, P. Abeywickrema, B. Bonneux, et al., “Structural and Mechanistic Insights into the Inhibition of respiratory Syncytial Virus Polymerase by a Non-nucleoside Inhibitor,” Communications Biology 6, no. 1 (2023): 1074.

[271] M. T. Tran, S. Grosse, R. J. Carbajo, et al., “Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors,” Acs Medicinal Chemistry Letters 15, no. 9 (2024): 1549-1558.

[272] S. Grosse, L. Cooymans, W. Embrechts, et al., “Discovery of Gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors,” Journal of Medicinal Chemistry 67, no. 16 (2024): 13723-13736.

[273] M. Liuzzi, S. W. Mason, M. Cartier, et al., “Inhibitors of respiratory Syncytial Virus Replication Target Cotranscriptional mRNA Guanylylation by Viral RNA-dependent RNA Polymerase,” Journal of Virology 79, no. 20 (2005): 13105-13115.

[274] M. R. Braun, L. R. Deflubé, S. L. Noton, et al., “RNA Elongation by respiratory Syncytial Virus Polymerase Is Calibrated by Conserved Region V,” Plos Pathogens 13, no. 12 (2017): e1006803.

[275] Q. Guo, J. Qian, Q. Zeng, et al., “Characterization of an Orally Available respiratory Syncytial Virus L Protein Polymerase Inhibitor DZ7487,” American journal of translational research 15, no. 3 (2023): 1680-1692.

[276] R. G. Tawar, S. Duquerroy, C. Vonrhein, et al., “Crystal Structure of a Nucleocapsid-Like Nucleoprotein-RNA Complex of respiratory Syncytial Virus,” Science 326, no. 5957 (2009): 1279-1283.

[277] M. Galloux, B. Tarus, I. Blazevic, et al., “Characterization of a Viral Phosphoprotein Binding Site on the Surface of the respiratory Syncytial Nucleoprotein,” Journal of Virology 86, no. 16 (2012): 8375-8387.

[278] J. Chapman, E. Abbott, D. G. Alber, et al., “RSV604, a Novel Inhibitor of respiratory Syncytial Virus Replication,” Antimicrobial Agents and Chemotherapy 51, no. 9 (2007): 3346-3353.

[279] S. Challa, A. D. Scott, O. Yuzhakov, et al., “Mechanism of Action for respiratory Syncytial Virus Inhibitor RSV604,” Antimicrobial Agents and Chemotherapy 59, no. 2 (2015): 1080-1087.

[280] J. Chapman and S. Cockerill, “Discovery and Development of RSV604,” Antiviral Drugs (2011): 367-382.

[281] S. M. Elbashir, J. Harborth, W. Lendeckel, et al., “Duplexes of 21-nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,” Nature 411, no. 6836 (2001): 494-498.

[282] R. Alvarez, S. Elbashir, T. Borland, et al., “RNA Interference-mediated Silencing of the respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy,” Antimicrobial Agents and Chemotherapy 53, no. 9 (2009): 3952-3962.

[283] J. DeVincenzo, J. E. Cehelsky, R. Alvarez, et al., “Evaluation of the Safety, Tolerability and Pharmacokinetics of ALN-RSV01, a Novel RNAi Antiviral Therapeutic Directed against respiratory Syncytial Virus (RSV),” Antiviral Research 77, no. 3 (2008): 225-231.

[284] J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, et al., “A Randomized, Double-blind, Placebo-controlled Study of an RNAi-based Therapy Directed against respiratory Syncytial Virus,” PNAS 107, no. 19 (2010): 8800-8805.

[285] A. Pelaez, G. M. Lyon, S. D. Force, et al., “Efficacy of Oral Ribavirin in Lung Transplant Patients with respiratory Syncytial Virus Lower respiratory Tract Infection,” Journal of Heart and Lung Transplantation 28, no. 1 (2009): 67-71.

[286] J. L. Todd and S. M. Palmer, “Bronchiolitis Obliterans Syndrome: the Final Frontier for Lung Transplantation,” Chest 140, no. 2 (2011): 502-508.

[287] M. R. Zamora, M. Budev, M. Rolfe, et al., “RNA Interference Therapy in Lung Transplant Patients Infected with respiratory Syncytial Virus,” American Journal of Respiratory and Critical Care Medicine 183, no. 4 (2011): 531-538.

[288] J. Gottlieb, M. R. Zamora, T. Hodges, et al., “ALN-RSV01 for Prevention of Bronchiolitis Obliterans Syndrome after respiratory Syncytial Virus Infection in Lung Transplant Recipients,” Journal of Heart and Lung Transplantation 35, no. 2 (2016): 213-221.

[289] M. H. J. Rhodin, N. V. McAllister, J. Castillo, et al., “EDP-938, a Novel Nucleoprotein Inhibitor of respiratory Syncytial Virus, Demonstrates Potent Antiviral Activities in Vitro and in a Non-human Primate Model,” Plos Pathogens 17, no. 3 (2021): e1009428.

[290] R. E. Levene, J. DeVincenzo, A. L. Conery, et al., “EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus,” Journal of Infectious Diseases 231, no. 2 (2025): e290-e298.

[291] A. Ahmad, K. Eze, N. Noulin, et al., “EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge,” New England Journal of Medicine 386, no. 7 (2022): 655-666.

[292] R. Ghildyal, A. Ho, and D. A. Jans, “Central Role of the respiratory Syncytial Virus Matrix Protein in Infection,” Fems Microbiology Review 30, no. 5 (2006): 692-705.

[293] A. Förster, G. N. Maertens, P. J. Farrell, et al., “Dimerization of Matrix Protein Is Required for Budding of respiratory Syncytial Virus,” Journal of Virology 89, no. 8 (2015): 4624-4635.

[294] A. P. Schmitt and R. A. Lamb, “Escaping from the Cell: Assembly and Budding of Negative-strand RNA Viruses,” Current Topics in Microbiology and Immunology 283 (2004): 145-196.

[295] A. Radhakrishnan, D. Yeo, G. Brown, et al., “Protein Analysis of Purified respiratory Syncytial Virus Particles Reveals an Important Role for Heat Shock Protein 90 in Virus Particle Assembly,” Molecular & Cellular Proteomics 9, no. 9 (2010): 1829-1848.

[296] V. Miazza, G. Mottet-Osman, S. Startchick, et al., “Sendai Virus Induced Cytoplasmic Actin Remodeling Correlates with Efficient Virus Particle Production,” Virology 410, no. 1 (2011): 7-16.

[297] G. Brown, C. E. Jeffree, T. McDonald, et al., “Analysis of the Interaction between respiratory Syncytial Virus and Lipid-rafts in Hep2 Cells during Infection,” Virology 327, no. 2 (2004): 175-185.

[298] G. Cosentino, K. Marougka, A. Desquesnes, et al., “Respiratory Syncytial Virus Ribonucleoproteins Hijack Microtubule Rab11 Dependent Transport for Intracellular Trafficking,” Plos Pathogens 18, no. 7 (2022): e1010619.

[299] R. Ghildyal, A. Ho, M. Dias, et al., “The respiratory Syncytial Virus Matrix Protein Possesses a Crm1-mediated Nuclear Export Mechanism,” Journal of Virology 83, no. 11 (2009): 5353-5362.

[300] R. Ghildyal, A. Ho, K. M. Wagstaff, et al., “Nuclear Import of the respiratory Syncytial Virus Matrix Protein Is Mediated by Importin beta1 Independent of Importin Alpha,” Biochemistry 44, no. 38 (2005): 12887-12895.

[301] C. Mathew, S. Tamir, R. A. Tripp, et al., “Reversible Disruption of XPO1-mediated Nuclear Export Inhibits respiratory Syncytial Virus (RSV) Replication,” Scientific Reports 11, no. 1 (2021): 19223.

[302] R. Ghildyal, C. Baulch-Brown, J. Mills, et al., “The Matrix Protein of Human respiratory Syncytial Virus Localises to the Nucleus of Infected Cells and Inhibits Transcription,” Archives of Virology 148, no. 7 (2003): 1419-1429.

[303] S. Shahriari, K. J. Wei, and R. Ghildyal, “Respiratory Syncytial Virus Matrix (M) Protein Interacts with Actin in Vitro and in Cell Culture,” Viruses 10, no. 10 (2018).

[304] P. A. Jorquera, C. Mathew, J. Pickens, et al., “Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication in Vitro,” Journal of Virology 93, no. 4 (2019).

[305] O. Perwitasari, S. Johnson, X. Yan, et al., “Antiviral Efficacy of Verdinexor in Vivo in Two Animal Models of Influenza A Virus Infection,” PLoS ONE 11, no. 11 (2016): e0167221.

[306] D. G. Widman, S. Gornisiewicz, S. Shacham, et al., “In Vitro Toxicity and Efficacy of verdinexor, an Exportin 1 Inhibitor, on Opportunistic Viruses Affecting Immunocompromised Individuals,” PLoS ONE 13, no. 10 (2018): e0200043.

[307] M. R. Braun, S. L. Noton, E. L. Blanchard, et al., “Respiratory Syncytial Virus M2-1 Protein Associates Non-specifically with Viral Messenger RNA and with Specific Cellular Messenger RNA Transcripts,” Plos Pathogens 17, no. 5 (2021): e1009589.

[308] S. J. Tanner, A. Ariza, C. A. Richard, et al., “Crystal Structure of the Essential Transcription Antiterminator M2-1 Protein of human respiratory Syncytial Virus and Implications of Its Phosphorylation,” PNAS 111, no. 4 (2014): 1580-1585.

[309] R. W. Hardy and G. W. Wertz, “The Cys(3)-His(1) Motif of the respiratory Syncytial Virus M2-1 Protein Is Essential for Protein Function,” Journal of Virology 74, no. 13 (2000): 5880-5885.

[310] M. S. Boukhvalova, G. A. Prince, and J. C. Blanco, “Inactivation of respiratory Syncytial Virus by Zinc Finger Reactive Compounds,” Virology journal 7 (2010): 20.

[311] Q. Zhang, H. Ye, C. Liu, et al., “PABP-driven Secondary Condensed Phase within RSV Inclusion Bodies Activates Viral mRNAs for Ribosomal Recruitment,” Virologica Sinica 39, no. 2 (2024): 235-250.

[312] M. E. Lindquist, A. W. Lifland, T. J. Utley, et al., “Respiratory Syncytial Virus Induces Host RNA Stress Granules to Facilitate Viral Replication,” Journal of Virology 84, no. 23 (2010): 12274-12284.

[313] C. Carromeu, F. M. Simabuco, R. E. Tamura, et al., “Intracellular Localization of human respiratory Syncytial Virus L Protein,” Archives of Virology 152, no. 12 (2007): 2259-2263.

[314] J. García, B. García-Barreno, A. Vivo, et al., “Cytoplasmic Inclusions of respiratory Syncytial Virus-infected Cells: Formation of Inclusion Bodies in Transfected Cells That Coexpress the Nucleoprotein, the Phosphoprotein, and the 22K Protein,” Virology 195, no. 1 (1993): 243-247.

[315] A. W. Lifland, J. Jung, E. Alonas, et al., “Human respiratory Syncytial Virus Nucleoprotein and Inclusion Bodies Antagonize the Innate Immune Response Mediated by MDA5 and MAVS,” Journal of Virology 86, no. 15 (2012): 8245-8258.

[316] V. Rincheval, M. Lelek, E. Gault, et al., “Functional Organization of Cytoplasmic Inclusion Bodies in Cells Infected by respiratory Syncytial Virus,” Nature Communications 8, no. 1 (2017): 563.

[317] J. Risso-Ballester, M. Galloux, J. Cao, et al., “A Condensate-hardening Drug Blocks RSV Replication in Vivo,” Nature 595, no. 7868 (2021): 596-599.

[318] C. Diot, C. A. Richard, J. Risso-Ballester, et al., “Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein,” International Journal of Molecular Sciences 24, no. 18 (2023): 13862.

[319] J. E. Evans, P. A. Cane, and C. R. Pringle, “Expression and Characterisation of the NS1 and NS2 Proteins of respiratory Syncytial Virus,” Virus Research 43, no. 2 (1996): 155-161.

[320] K. M. Spann, K. C. Tran, and P. L. Collins, “Effects of Nonstructural Proteins NS1 and NS2 of human respiratory Syncytial Virus on Interferon Regulatory Factor 3, NF-kappaB, and Proinflammatory Cytokines,” Journal of Virology 79, no. 9 (2005): 5353-5362.

[321] S. Chatterjee, P. Luthra, E. Esaulova, et al., “Structural Basis for human respiratory Syncytial Virus NS1-mediated Modulation of Host Responses,” Nature microbiology 2 (2017): 17101.

[322] E. Pretel, G. Camporeale, and G. de Prat-Gay, “The Non-structural NS1 Protein Unique to respiratory Syncytial Virus: a Two-state Folding Monomer in Quasi-equilibrium with a Stable Spherical Oligomer,” PLoS ONE 8, no. 9 (2013): e74338.

[323] K. Sedeyn, B. Schepens, and X. Saelens, “Respiratory Syncytial Virus Nonstructural Proteins 1 and 2: Exceptional Disrupters of Innate Immune Responses,” Plos Pathogens 15, no. 10 (2019): e1007984.

[324] S. Boyapalle, T. Wong, J. Garay, et al., “Respiratory Syncytial Virus NS1 Protein Colocalizes with Mitochondrial Antiviral Signaling Protein MAVS Following Infection,” PLoS ONE 7, no. 2 (2012): e29386.

[325] Z. Ling, K. C. Tran, and M. N. Teng, “Human respiratory Syncytial Virus Nonstructural Protein NS2 Antagonizes the Activation of Beta Interferon Transcription by Interacting with RIG-I,” Journal of Virology 83, no. 8 (2009): 3734-3742.

[326] R. Goswami, T. Majumdar, J. Dhar, et al., “Viral Degradasome Hijacks Mitochondria to Suppress Innate Immunity,” Cell Research 23, no. 8 (2013): 1025-1042.

[327] J. Pei, N. R. Beri, A. J. Zou, et al., “Nuclear-localized human respiratory Syncytial Virus NS1 Protein Modulates Host Gene Transcription,” Cell Reports 37, no. 2 (2021): 109803.

[328] P. A. González, C. E. Prado, E. D. Leiva, et al., “Respiratory Syncytial Virus Impairs T Cell Activation by Preventing Synapse Assembly with Dendritic Cells,” PNAS 105, no. 39 (2008): 14999-15004.

[329] S. Munir, P. Hillyer, C. Le Nouën, et al., “Respiratory Syncytial Virus Interferon Antagonist NS1 Protein Suppresses and Skews the human T Lymphocyte Response,” Plos Pathogens 7, no. 4 (2011): e1001336.

[330] K. M. Spann, K. C. Tran, B. Chi, et al., “Suppression of the Induction of Alpha, Beta, and Lambda Interferons by the NS1 and NS2 Proteins of human respiratory Syncytial Virus in human Epithelial Cells and Macrophages [corrected],” Journal of Virology 78, no. 8 (2004): 4363-4369.

[331] H. M. Woo, K. S. Kim, J. M. Lee, et al., “Single-stranded DNA Aptamer That Specifically Binds to the Influenza Virus NS1 Protein Suppresses Interferon Antagonism,” Antiviral Research 100, no. 2 (2013): 337-345.

[332] Z. Feng, L. Xu, and Z. Xie, “Receptors for Respiratory Syncytial Virus Infection and Host Factors Regulating the Life Cycle of Respiratory Syncytial Virus,” Frontiers in Cellular and Infection Microbiology 12 (2022): 858629.

[333] E. A. Kurt-Jones, L. Popova, L. Kwinn, et al., “Pattern Recognition Receptors TLR4 and CD14 Mediate Response to respiratory Syncytial Virus,” Nature Immunology 1, no. 5 (2000): 398-401.

[334] A. R. Salkind, J. E. Nichols, and N. J. Roberts, “Suppressed Expression of ICAM-1 and LFA-1 and Abrogation of Leukocyte Collaboration after Exposure of human Mononuclear Leukocytes to respiratory Syncytial Virus in Vitro. Comparison with Exposure to Influenza Virus,” Journal of Clinical Investigation 88, no. 2 (1991): 505-511.

[335] R. Malhotra, M. Ward, H. Bright, et al., “Isolation and Characterisation of Potential respiratory Syncytial Virus Receptor(s) on Epithelial Cells,” Microbes and Infection 5, no. 2 (2003): 123-133.

[336] M. G. Currier, S. Lee, C. C. Stobart, et al., “EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression,” Plos Pathogens 12, no. 5 (2016): e1005622.

[337] C. D. Griffiths, L. M. Bilawchuk, J. E. McDonough, et al., “IGF1R is an Entry Receptor for respiratory Syncytial Virus,” Nature 583, no. 7817 (2020): 615-619.

[338] A. Alesci, N. Nicosia, A. Fumia, et al., “Resveratrol and Immune Cells: a Link to Improve Human Health,” Molecules (Basel, Switzerland) 27, no. 2 (2022).

[339] Y. Xiong, K. Tao, T. Li, et al., “Resveratrol Inhibits respiratory Syncytial Virus Replication by Targeting Heparan Sulfate Proteoglycans,” Food & Function 15, no. 4 (2024): 1948-1962.

[340] B. Kaczmarek, “Tannic Acid with Antiviral and Antibacterial Activity as a Promising Component of Biomaterials-A Minireview,” Materials (Basel) 13, no. 14 (2020): 3224.

[341] N. J. Barrows, R. K. Campos, S. T. Powell, et al., “A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection,” Cell Host & Microbe 20, no. 2 (2016): 259-270.

[342] P. Ruan, P. Dai, Y. Mao, et al., “The in Vitro and in Vivo Antiviral Effects of IGF1R Inhibitors against respiratory Syncytial Virus Infection,” Journal of Biomolecular Structure & Dynamics (2024): 1-12.

[343] J. Feng, Z. Cao, L. Wang, et al., “Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection,” Journal of Innate Immunity 9, no. 4 (2017): 419-435.

[344] Z. Li, X. Qu, X. Liu, et al., “GBP5 Is an Interferon-Induced Inhibitor of Respiratory Syncytial Virus,” Journal of Virology 94, no. 21 (2020): e01407-e01420.

[345] Z. Han, J. Rao, Z. Xie, et al., “Chemokine (C-X-C Motif) Ligand 4 Is a Restrictor of Respiratory Syncytial Virus Infection and an Indicator of Clinical Severity,” American Journal of Respiratory and Critical Care Medicine 202, no. 5 (2020): 717-729.

[346] S. T. O'Leary, A. B. Yonts, C. Gaviria-Agudelo, et al., “Summer 2023 ACIP Update: RSV Prevention and Updated Recommendations on Other Vaccines,” Pediatrics 152, no. 5 (2023).

[347] J. M. Jones, K. E. Fleming-Dutra, M. M. Prill, et al., “Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023,” Mmwr Morbidity and Mortality Weekly Report 72, no. 34 (2023): 920-925.

[348] K. E. Fleming-Dutra, J. M. Jones, L. E. Roper, et al., “Use of the Pfizer Respiratory Syncytial Virus Vaccine during Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023,” Mmwr Morbidity and Mortality Weekly Report 72, no. 41 (2023): 1115-1122.

[349] I. Dieussaert, J. Hyung Kim, and S. Luik, “RSV Prefusion F Protein-Based Maternal Vaccine—Preterm Birth and Other Outcomes,” New England Journal of Medicine 390, no. 11 (2024): 1009-1021.

[350] B. Kampmann, S. A. Madhi, I. Munjal, et al., “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants,” New England Journal of Medicine 388, no. 16 (2023): 1451-1464.

[351] O. J. Jasset, P. A. Lopez Zapana, Z. Bahadir, et al., “Enhanced Placental Antibody Transfer Efficiency with Longer Interval between Maternal respiratory Syncytial Virus Vaccination and Birth,” American Journal of Obstetrics and Gynecology 232, no. 6 (2025): 554. e1-e15.

[352] N. Plock, J. R. Sachs, X. Zang, et al., “Efficacy of Monoclonal Antibodies and Maternal Vaccination for Prophylaxis of respiratory Syncytial Virus Disease,” Communications Medicine (London) 5, no. 1 (2025): 119.

[353] M. G. Ison, A. Papi, E. Athan, et al., “Efficacy, Safety, and Immunogenicity of the AS01(E)-adjuvanted respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults over Three respiratory Syncytial Virus Seasons (AReSVi-006): a Multicentre, Randomised, Observer-blinded, Placebo-controlled, Phase 3 Trial,” Lancet Respiratory Medicine 13, no. 6 (2025): 517-529.

[354] A. P. S. Munro, S. B. Drysdale, K. Cathie, et al., “180-day Efficacy of nirsevimab against Hospitalisation for respiratory Syncytial Virus Lower respiratory Tract Infections in Infants (HARMONIE): a Randomised, Controlled, Phase 3b Trial,” Lancet Child & Adolescent Health 9, no. 6 (2025): 404-412.

[355] K. Stray, M. Perron, D. P. Porter, et al., “Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected with RSV,” Journal of Infectious Diseases 222, no. 9 (2020): 1468-1477.

[356] L. Dai, J. Song, L. Xu, et al., “A Protective human Antibody against respiratory Syncytial Virus by Targeting a Prefusion Epitope across Sites IV and V of the Viral Fusion Glycoprotein,” Hlife 1, no. 1 (2023): 12-25.

[357] Y. Gao, J. Cao, P. Xing, et al., “Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus in Vitro,” Molecules (Basel, Switzerland) 26, no. 9 (2021): 2607.

[358] G. F. Gao, J. A. Hoffmann, C. Walzer, et al., “Global Public Health Crisis Response: A Roundtable Discussion with Professor George Fu Gao, Professor Jules A Hoffmann, Professor Chris Walzer and Professor Jiahai Lu,” Hlife 1, no. 2 (2023): 63-70.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.